Connect with us

News

We must act to remove the barriers to digital health, say experts

Published

on

Women’s health experts have called for action to remove the “unacceptable” barriers to digital health.

Digital health technologies have been shown to improve women’s health and promote equity.

A new WHO/Europe report has found that digital health tools are particularly useful in areas related to gynaecology, obstetrics, psychiatry and nutrition, improving access to healthcare services and empowering women to have more autonomy.

However, experts have warned that barriers, such as digital literacy and limited access to technologies, could prevent many girls and women from using these innovations.

“Addressing the barriers to digital health technologies is crucial for ensuring all women benefit equitably,” Dr Eboni January, board-certified physician and surgeon, told Femtech World.

“Ensuring that digital health solutions are user-friendly and available in various languages can significantly enhance accessibility. Additionally, providing low-cost or subsidised devices and internet access can help alleviate financial barriers.”

Developing digital health technologies that are culturally sensitive and relevant to the diverse needs of women is also crucial, said January.

“Engaging with community leaders and stakeholders can help ensure that these technologies are designed with cultural considerations in mind.”

Dr Louise Newson, GP and menopause specialist, said community-based digital education initiatives could help women develop the skills needed to navigate and utilise digital health tools effectively.

“Working with tech companies and policymakers is also essential to ensure that affordable devices and internet access are available to all, particularly in underserved communities,” she explained.

Dr Louise Newson, GP and menopause specialist

Women and girls are 25 per cent less likely than men to have sufficient knowledge and digital skills to use technology. Digital health disparities disproportionately affect marginalised women, making it challenging for them to access healthcare services.

Dr Emilia Pasiah, board-certified physician specialised in family medicine, said digital literacy programmes are essential.

“Educating women on how to use digital health tools effectively can empower them to take control of their health,” she told Femtech World.

“Healthcare providers must be trained to incorporate digital tools into their practice and advocate their use among patients. This can enhance trust and promote the benefits of digital health solutions.

“Addressing privacy and security concerns is also crucial to gaining trust. Ensuring robust data protection and transparency about how data is used can alleviate fears and encourage the adoption of digital health tools.”

This privacy aspect might be particularly crucial in regions or communities with stigma or social barriers.

Melissa Snover, founder and CEO of Nourished, added: “We need to provide education and resources to boost women’s digital skills, and make these technologies accessible to everyone, regardless of their socioeconomic background. This means developing affordable solutions and implementing supportive policies tailored to the unique needs of underserved communities.”

When considering health outcomes for women facing socioeconomic barriers, Annie Thériault, managing partner at Cross-Border Impact Ventures, said it is “critical” that we recognise these groups would only take up interventions that are heavily subsidised or free.

“Public healthcare systems and insurance providers have a role to play in addressing barriers to digital health solutions and should implement mechanisms to make digital health services affordable and reimbursable,” she said.

“Leveraging the capacity and ubiquity of private sector players can also significantly impact digital health uptake. Hardware manufacturers have a tremendous opportunity to drive traffic to their storefronts by partnering with public health entities that could promote their solutions and provide digital health training in-store.”

Companies like Apple, Thériault said, are already providing digital literacy sessions in-store, though this is largely unknown.

Some, however, believe the barriers to digital health adoption should be addressed early on.

According to Theresa Neil, founder and CEO of Guidea, creating accessible and equitable digital health solutions should start with culturally competent research.

“Culturally competent research means planning and executing research studies to include women of all abilities, literacy levels, access to technology, and caregiving responsibilities.

“Early market and UX research could identify opportunities where technology can improve patient outcomes, and where technology may be just one piece of a broader solution.”

To receive the Femtech World newsletter, sign up here.

Diagnosis

Lung cancer drug shows breast cancer potential

Published

on

Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.

PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.

Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.

The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.

In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.

Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.

Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.

Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”

John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”

Continue Reading

Insight

Higher nighttime temps linked to increased risk of autism diagnosis in children – study

Published

on

Nighttime temperatures during pregnancy may be linked to a higher chance of an autism diagnosis in children, a recent study suggests.

The research tracked nearly 295,000 mother-child pairs in Southern California from 2001 to 2014 and linked warmer overnight temperatures with higher risk in early and late pregnancy.

Children of mothers exposed to higher than typical nighttime temperatures during weeks one to 10 of pregnancy had a 15 per cent higher risk of an autism diagnosis.

Exposure during weeks 30 to 37 was linked to a 13 per cent higher risk.

 Lead author David Luglio, a post-doctoral fellow at Tulane University, said: “A key takeaway is that we identified specific windows when a mother and her developing child can be most affected by exposures to higher nighttime temperatures.

“This is critical and hopefully can help mothers prepare accordingly.”

The study is described as the first to examine how temperature may affect fetal neurodevelopment, the process by which a baby’s brain and nervous system form during pregnancy.

Extreme temperatures linked to increased risk were classified as above the 90th percentile, meaning 3.6°F hotter than average, and the 99th percentile, 5.6°F above average.

The association held even after researchers accounted for factors such as neighbourhood conditions, vegetation and fine-particle air pollution.

The study could not account for other factors such as access to air conditioning. Researchers did not find the same association with daytime temperatures, potentially because people spend more time away from home during the day.

“Heat waves are becoming more frequent, and people may only think of the dangers of daytime heat exposure,” said Mostafijur Rahman, assistant professor of environmental health sciences at Tulane University.

“These results indicate a strong association between high nighttime temperatures during pregnancy and autism risk in children and show that we need to think about exposure to heat around the clock.”

The study did not examine how higher temperatures at night might affect prenatal development, though Luglio said it is possible that warmer nights disrupt sleep for pregnant mothers.

Previous research has suggested insufficient sleep during pregnancy may be linked to a higher risk of neurocognitive delays in children.

“Extreme heat exposure during pregnancy has been linked to a range of adverse health outcomes, including prenatal neurodevelopment delays and complications with an embryo’s development of a central nervous system,” Luglio said.

“The goal of our study was to specifically explore the link between prenatal heat exposure and autism diagnoses for the first time.”

Continue Reading

Entrepreneur

Kindbody unveils next-gen fertility platform

Published

on

Kindbody has launched a fertility platform integrating AI with clinical care and patient support for employers and health plans.

The platform will enter a pilot with select Kindbody employer clients in 2026, covering over three million lives, ahead of wider availability in 2027.

Building on the company’s clinical model, the platform aims to improve outcomes and cost efficiency across family-building journeys. It connects Kindbody-owned clinics, partner clinics and an integrated clinical app.

The app offers virtual care across conception, pregnancy and reproductive health, extending through the menopause transition.

Launch features include updates in medication management, third-party reproduction, adoption, pregnancy, men’s health and global programme design.

David Stern, chief executive of Kindbody, said: “With our next-generation fertility platform, Kindbody is redefining what comprehensive, intelligent and affordable family-building care looks like for employers, health plans and patients.

“By unifying best-in-class clinical care, AI-driven intelligence and whole-person support, we are making it easier and more cost-effective for more people to build the families they envision.”

Kindbody has expanded access via its national network of IVF centres, including IVIRMA, Inception Fertility and Ivy Fertility.

A new Fertility Medication Portal is designed to streamline authorisations so medicines can be dispensed on time, giving patients visibility from prescription to coverage, pharmacy fulfilment and delivery tracking.

Through KindMan, men’s health education, digital resources and integrated clinical care are expanding, including hormone management programmes.

Services cover andropause (age-related testosterone decline), erectile dysfunction, low testosterone and other male reproductive conditions.

Specialist fertility care includes semen analysis, diagnostic testing, male hormone panels, genetic testing, surgical sperm extraction and sperm cryopreservation.

Launching in the second quarter, a pregnancy support app will act as a digital companion for expecting and new parents, with resources, interactive tools and clinical assessments to identify social drivers of health and mental health needs during pregnancy and beyond.

Kindbody’s physician-led menopause programme provides consultations with board-certified obstetricians and gynaecologists to diagnose, treat and manage menopausal symptoms, including hormone replacement therapy where appropriate, with support from nutritionists, mental health therapists and pelvic floor specialists.

AI and analytics will be embedded across the care journey. An AI care navigator will guide employees from benefit activation through intake, triage and scheduling.

Tools will track benefits and treatment plans, showing coverage and expected out-of-pocket costs at each step.

AI-supported scribing will assist clinicians with documentation, and a predictor tool will estimate a patient’s likelihood of having a baby across different treatment paths.

In 2027, Kindbody plans a savings model for eligible large employers that it says will guarantee lower total fertility spend while improving clinical efficiency and patient experience.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.